CHICAGO, Feb. 20, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Durata's Chief Executive Officer Paul R. Edick will present an overview of the company at the Cowen & Company Healthcare Conference in Boston, MA. The Durata presentation will take place at The Boston Marriott Copley Place on Wednesday, March 6, 2013 at 9:20 a.m. EST.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 study and enrollment in its DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.The Durata Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16463 Forward-looking statements Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Investor Relations and Public Affairs Contact Allison Wey - Durata Therapeutics Vice President, Investor Relations and Public Affairs (312)219-7017 - email@example.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts